 |
PDBsum entry 1g5s
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
|
|
|
|
|
|
|
Cell cycle/transferase
|
PDB id
|
|
|
|
1g5s
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
|
References listed in PDB file
|
 |
|
Key reference
|
 |
|
Title
|
 |
Crystal structure of human cyclin-Dependent kinase 2 in complex with the adenine-Derived inhibitor h717.
|
 |
|
Authors
|
 |
M.K.Dreyer,
D.R.Borcherding,
J.A.Dumont,
N.P.Peet,
J.T.Tsay,
P.S.Wright,
A.J.Bitonti,
J.Shen,
S.H.Kim.
|
 |
|
Ref.
|
 |
J Med Chem, 2001,
44,
524-530.
[DOI no: ]
|
 |
|
PubMed id
|
 |
|
 |
 |
|
Abstract
|
 |
|
Cyclin-dependent kinases (CDKs) are regulatory proteins of the eukaryotic cell
cycle. They act after association with different cyclins, the concentrations of
which vary throughout the progression of the cell cycle. As central mediators of
cell growth, CDKs are potential targets for inhibitory molecules that would
allow disruption of the cell cycle in order to evoke an antiproliferative effect
and may therefore be useful as cancer therapeutics. We synthesized several
inhibitory 2,6,9-trisubstituted purine derivatives and solved the crystal
structure of one of these compounds, H717, in complex with human CDK2 at 2.6 A
resolution. The orientation of the C2-p-diaminocyclohexyl portion of the
inhibitor is strikingly different from those of similar moieties in other
related inhibitor complexes. The N9-cyclopentyl ring fully occupies a space in
the enzyme which is otherwise empty, while the C6-N-aminobenzyl substituent
points out of the ATP-binding site. The structure provides a basis for the
further development of more potent inhibitory drugs.
|
 |
|
Secondary reference #1
|
 |
|
Title
|
 |
Purification and crystallization of human cyclin-Dependent kinase 2.
|
 |
|
Authors
|
 |
J.Rosenblatt,
H.De bondt,
J.Jancarik,
D.O.Morgan,
S.H.Kim.
|
 |
|
Ref.
|
 |
J Mol Biol, 1993,
230,
1317-1319.
|
 |
|
PubMed id
|
 |
|
 |
 |
|
|
 |
|
|
|
|
 |